Total Funding
52
13
Total FundingPost-IPO Debt raised
Growth Score
-6 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
1936836
Opexa Therapeutics develops patient-specific immunotherapies for the treatment of multiple sclerosis.
David Jorden: Bord of DirectorsPast Role: Fayez Sarofim & Co., Principal
Jingwu Zang: Scientific Founder
About the Company
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific immunotherapies for the treatment of multiple sclerosis. The Company’s leading therapy candidate, Tcelna™, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the
treatment of Secondary Progressive Multiple Sclerosis.
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders.
Opexa is located in The Woodlands, Texas north of Houston on one acre of forested land and houses its cGMP facility, research laboratories and corporate offices.
